Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 19, 2017
Reporting Period: First Quarter 2017
This filing announces the results of operations for the first quarter of 2017. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a notification of the results rather than a detailed financial statement.
Non-GAAP Adjustments Disclosed: The company utilizes non-GAAP measures that exclude:
- Expenses associated with acquisitions, restructuring actions, and cost reduction initiatives.
- Gain on the sale of the Medical Optics business.
- Foreign exchange loss related to Venezuela.
- Resolution of various tax positions from prior years.
- Intangible amortization expense.
Material Changes
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. It notes that the results include adjustments for unusual or unpredictable factors such as the Medical Optics sale and Venezuela-related foreign exchange losses.
Guidance, Outlook, and Management Commentary
Management Commentary: Abbott's management states that non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business performance. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Guidance and Risks: The provided text does not contain specific forward-looking guidance, updated outlook figures, or a detailed discussion of risks and contingencies beyond the mention of unusual items affecting the current quarter.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings, specifically regarding the Medical Optics sale gain and Venezuela foreign exchange loss.
- Confirm the impact of restructuring and acquisition-related expenses on operating margins.
- Check for any updated full-year guidance provided in the referenced press release.